VP16
PreclinicalSmall molecule
VP16 is one of 12 small molecule programs targeting Acute Lymphoblastic Leukaemia. It is currently in Preclinical.
1
Indications
8
Total Trials
1
Active Trials
11
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
14 competitors in Acute Lymphoblastic Leukaemia
#DrugCompanyPhaseTrials
1Cytoxan
BBaxter Healthcare Corporation
Phase 2
Mesnex
BBaxter Healthcare Corporation
Phase 2
Campath
GGenzyme, a Sanofi Company
Phase 2
Fludara
SanofiPhase 1
Tepadina
Jazz PharmaceuticalsPreclinical
AUTO1
AAutolus Limited
Phase 2
Busulfex
Akero TherapeuticsPreclinical
Noxafil
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Preclinical
Grafapex
MMedexus Pharma, Inc.
Preclinical
CAR-T Cell Therapy
TThe First Affiliated Hospital of Soochow University
Phase 1
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Acute Lymphoblastic Leukemia3 trials
Allogeneic Stem Cell Transplantation1 trial
Lymphoblastic Lymphoma1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for VP16. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- SSt. Anna Kinderkrebsforschung